1. Home
  2. XNET vs OABI Comparison

XNET vs OABI Comparison

Compare XNET & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$4.93

Market Cap

358.4M

Sector

Technology

ML Signal

HOLD

Logo OmniAb Inc.

OABI

OmniAb Inc.

HOLD

Current Price

$4.38

Market Cap

294.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNET
OABI
Founded
2003
2012
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
358.4M
294.3M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
XNET
OABI
Price
$4.93
$4.38
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
219.1K
1.8M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.56
EPS
N/A
N/A
Revenue
N/A
$18,666,000.00
Revenue This Year
N/A
$52.42
Revenue Next Year
N/A
$64.69
P/E Ratio
$0.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.52
$1.32
52 Week High
$11.03
$4.93

Technical Indicators

Market Signals
Indicator
XNET
OABI
Relative Strength Index (RSI) 42.00 72.78
Support Level $4.78 $1.71
Resistance Level $6.09 N/A
Average True Range (ATR) 0.19 0.30
MACD 0.01 0.04
Stochastic Oscillator 35.71 68.10

Price Performance

Historical Comparison
XNET
OABI

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: